(Q35586791)

9 August 2017

1 reference

title

Aromatase inhibitors versus tamoxifen for management of postmenopausal breast cancer in the advanced disease and neoadjuvant settings (English)

1 reference

9 August 2017

1 reference

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00373-X

3 April 2024

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00373-X

3 April 2024

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00373-X

3 April 2024

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00373-X

3 April 2024

2

Vera J Suman

1 reference

9 August 2017

1

James N Ingle

1 reference

9 August 2017

language of work or name

1 reference

1 September 2003

1 reference

full work available at URL

9 August 2017

https://api.elsevier.com/content/article/PII:S096007600300373X?httpAccept=text/xml

1 reference

DOI

https://api.crossref.org/works/10.1016/S0960-0760(03)00373-X

https://api.elsevier.com/content/article/PII:S096007600300373X?httpAccept=text/plain

3 April 2024

1 reference

DOI

https://api.crossref.org/works/10.1016/S0960-0760(03)00373-X

The Journal of Steroid Biochemistry and Molecular Biology

3 April 2024

published in

1 reference

9 August 2017

86

1 reference

9 August 2017

3-5

1 reference

9 August 2017

313-319

1 reference

Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer

9 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900373-X

7 January 2021

Randomized trial of diethylstilbestrol vs. tamoxifen in postmenopausal women with metastatic breast cancer. An updated analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900373-X

7 January 2021

Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900373-X

7 January 2021

Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900373-X

7 January 2021

Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900373-X

7 January 2021

Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: results of two randomized double blind controlled multiinstitutional trials

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900373-X

7 January 2021

Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3).

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900373-X

7 January 2021

Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900373-X

7 January 2021

Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900373-X

7 January 2021

Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900373-X

7 January 2021

Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900373-X

7 January 2021

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900373-X

7 January 2021

Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900373-X

7 January 2021

Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900373-X

7 January 2021

Identifiers

DOI

1 reference

release_y2wv5skatvetvlmkq5pbtcvkfy

9 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/y2wv5skatvetvlmkq5pbtcvkfy

24 November 2022

mapped directly with Wikidata item

1 reference